20:41 , Jan 18, 2019 |  BC Week In Review  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
23:21 , Jan 17, 2019 |  BC Extra  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
23:28 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Cell culture and rat studies identified a positive allosteric modulator (PAM) of mGluR4 that could help treat catalepsy in PD. Optimization and testing in human mGluR4-expressing CHO cells of a previously...
00:58 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Prexton begins Phase II of foliglurax for PD

Prexton Therapeutics S.A. (Geneva, Switzerland) began the double-blind, placebo-controlled, European Phase II AMBLED trial to evaluate 10 and 30 mg doses of oral foliglurax (PXT002331) for 28 days in 165 patients with Parkinson’s disease (PD)...
20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
21:13 , Jan 27, 2017 |  BC Week In Review  |  Company News

Domain, Merck deal

Domain said it partnered with Merck to develop adenosine receptor inhibitors to treat cancer. Domain is eligible to receive an undisclosed upfront payment and milestones totaling €240 million ($257.5 million), plus royalties. Merck will fund...
00:42 , Jan 24, 2017 |  BC Extra  |  Company News

Domain, Merck KGaA in adenosine receptor deal

Domain Therapeutics S.A. (Strasbourg, France) said it partnered with Merck KGaA (Xetra:MRK) to develop adenosine receptor inhibitors to treat cancer. Domain is eligible to receive an undisclosed upfront payment and milestones totaling EUR 240 million...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

Domain Therapeutics, Mavalon Therapeutics deal

Domain formed single-asset, U.K.-based newco Mavalon Therapeutics with an investment of up to EUR9 million ($9.9 million) from Medicxi Ventures . Domain also granted Mavalon rights to positive allosteric modulators of metabotropic glutamate receptor subtype...
07:00 , Oct 18, 2016 |  BC Extra  |  Financial News

Domain launches PD newco Mavalon

Domain Therapeutics S.A. (Strasbourg, France) said it launched single-asset, U.K.-based Parkinson's disease newco Mavalon Therapeutics with an investment of up to EUR 9 million ($9.9 million) from Medicxi Ventures. According to Domain, Mavalon will develop...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

PXT002331: Phase I data

A double-blind, placebo-controlled, U.K. Phase I trial in 64 healthy volunteers showed that single and multiple ascending doses of oral PXT002331 were well tolerated. In 2013, Prexton exercised an option from Domain for an exclusive,...